"Methods: We searched PubMed, Google Scholar, Cochrane, and Embase for case reports using search terms 'Guillain-Barré Syndrome,' [GBS] 'COVID-19 Vaccines,' 'COVID-19,' and 'Case report' published till 1st August 2023 ...
Results: We conducted a comprehensive review of published case reports and documented 70 published case reports from peer-reviewed journals. A total of 103 individuals were described on those case reports; among them, the highest number that is 48 people developed GBS following AstraZeneca (Vaxzervia) vaccination followed by 23 after Pfizer, 8 after Johnson & Johnson, Moderna, 6 after Sinopharm, 5 after Sputnik, 2 after Sinovac, Corbevax and one after Vector-based COVID-19 vaccine ...
Discussion: The epidemiological relationship between COVID-19 vaccination and GBS is becoming clearer. The most common symptom of GBS, an autoimmune disorder of the peripheral nerve system, is rapidly progressing ascending paralysis. This study will be crucial for promoting early detection and treatment because GBS complications can result in serious morbidity and death.
We reviewed the onset of symptoms, clinical features, previous comorbidities, investigations, and outcomes of 103 patients aged between 13 and 87 with the COVID-19-associated GBS spectrum. Our study demonstrated a correlation between the COVID-19 vaccine and GBS; patients reported ascending progressive paraesthesia of distal lower and upper limbs following the administration of various COVID-19 vaccines."
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/